200 GSK Annual Report 2017 Notes to the financial statements continued 31.
Net debt continued Current assets Liquid investments are classified as available-for-sale investments.
At 31 December 2017, they included US Treasury Notes and other government bonds.
The effective interest rate on liquid investments at 31 December 2017 was approximately 1.0% 2016 approximately 0.7%.
Liquid investment balances at 31 December 2017 earning interest at floating rates amount to 78 million 2016 89 million.
Liquid investment balances at 31 December 2017 earning interest at fixed rates amount to nil million 2016 nil.
The effective interest rate on cash and cash equivalents at 31 December 2017 was approximately 1.3% 2016 approximately 1.3%.
Cash and cash equivalents at 31 December 2017 earning interest at floating and fixed rates amount to 3,832 million and 1 million respectively 2016 4,584 million and 3 million.
GSKs policy regarding the credit quality of cash and cash equivalents is referred to in Note 42, Financial instruments and related disclosures.
Short-term borrowings GSK has a $10 billion 7.4 billion US commercial paper programme, of which $0.7 billion 0.5 billion was in issue at 31 December 2017 2016 $1.4 billion 1.1 billion.
GSK also has 1.9 billion five year committed facilities and $2.5 billion 1.9 billion of 364 day committed facilities.
The five-year committed facilities were agreed in September 2015 and were extended by one year to 2021 in September 2016.
The 364 day committed facilities were agreed in August 2017.
Liquid investments, cash and cash equivalents were as shown in the table on page 199.
The weighted average interest rate on commercial paper borrowings at 31 December 2017 was 1.53% 2016 0.88%.
The weighted average interest rate on current bank loans and overdrafts at 31 December 2017 was 4.65% 2016 3.47%.
The average effective pre-swap interest rate of notes classified as short term at 31 December 2017 was 5.92% 2016 3.18%.
Long-term borrowings At the year-end, GSK had long-term borrowings of 14.3 billion 2016 14.7 billion of which 10.3 billion 2016 11.1 billion falls due in more than five years.
The average effective pre-swap interest rate of all notes in issue at 31 December 2017 was approximately 3.6% 2016 approximately 4.1%.
Long-term borrowings repayable after five years carry interest at effective rates between 1.07% and 6.66%, with repayment dates ranging from 2023 to 2045.
Pledged assets The Group held pledged investments in US Treasury Notes with a par value of $105 million 78 million, 2016 $105 million 85 million as security against irrevocable letters of credit issued on the Groups behalf in respect of the Groups self-insurance activity.
Provisions in respect of self-insurance are included within the provisions for legal and other disputes discussed in Note 29, Other provisions.
In addition, 20 million 2016 23 million of assets included in Note 22, Other non-current assets, which do not form part of Net debt, were pledged as collateral against future rental payments under operating lease arrangements entered into by Human Genome Sciences, Inc. prior to its acquisition by the Group.
Finance lease obligations 2017 2016 m m Rental payments due within one year 25 25 Rental payments due between one and two years 29 23 Rental payments due between two and three years 9 12 Rental payments due between three and four years 3 7 Rental payments due between four and five years 2 Rental payments due after five years 10 Total future rental payments 78 67 Future finance charges 12 3 Total finance lease obligations 66 64 32.
Contingent liabilities At 31 December 2017, contingent liabilities, comprising guarantees, discounted bills and other items arising in the normal course of business, amounted to 434 million 2016 281 million.
At 31 December 2017, 2 million 2016 1 million of financial assets were pledged as collateral for contingent liabilities.
Provision is made for the outcome of tax, legal and other disputes where it is both probable that the Group will suffer an outflow of funds and it is possible to make a reliable estimate of that outflow.
At 31 December 2017, other than for those disputes where provision has been made, it was not possible to make a reliable estimate of the potential outflow of funds that might be required to settle disputes where the possibility of there being an outflow was more than remote.
Descriptions of the significant tax, legal and other disputes to which the Group is a party are set out in Note 14, Taxation and Note 45, Legal proceedings.
